Clinical trials: NAFLD (Nonalcoholic Fatty Liver Disease)
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
NAFLD, Diabetes
DIAbetes and NAFLD
Non-alcoholic hepatic steatosis (NAFLD) is characterised by the excessive accumulation of triglycerides in the liver and is often associated, in the absence of significant alcohol consumption, with insulin resistance and…
- Conditions
- NAFLD, Diabetes, NASH, Fibrosis, Liver
- Trial name
- DIANA (NCT06315361)
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nonalcoholic Fatty Liver Disease, Physician
Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease
This trial studies patient and physician perspectives on non-alcoholic fatty liver disease. Using questionnaires and interviews, this trial may help researchers understand physicians' knowledge about the diagnosis, prognosis…
- Trial name
- NCT04132440
- Testing
- Interview, Questionnaire Administration
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease
The purpose of this research study is to find out about the usefulness of mindfulness for weight loss and improvement of physical and mental health in people who have non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Obesity
- Trial name
- NCT05130346
- Testing
- Mindfulness Based Stress Reduction (MBSR)
- Where
- United States
- Sponsor
- Virginia Commonwealth University
NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
- Trial name
- ENLIVEN (NCT04929483)
- Testing
- BIO89-100
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 222 people
- Sponsor
- 89bio, Inc.
NASH, NAFLD
Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD
This is a Phase Ib/II, randomized, double-blind, placebo-controlled, international multi-center clinical study to investigate the efficacy and safety of GH509 in subjects with NASH/NAFLD
- Trial name
- NCT05784779
- Testing
- GH509
- Where
- China
- Volunteers
- 180 people
- Sponsor
- 1Globe Biomedical Co., Ltd.
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Non-Alcoholic Fatty Liver Disease
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Over the past 30 years, the prevalence of childhood obesity in the United States has tripled from 5% to 15%. Major consequences of obesity include insulin resistance, type- 2 diabetes, cardiovascular disease and nonalcoholic…
- Trial name
- NCT01285362
- Testing
- Fish Oil Supplementation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Nonalcoholic Fatty Liver Disease
Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis
This is a controlled study to determine the effectiveness and safety of MB12066 in the treatment of adult patients with Nonalcoholic Fatty Liver Disease(NAFLD) except cirrhosis.
- Trial name
- NCT02029586
- Testing
- MB12066 200mg
- Where
- 10 sites in South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.
NAFLD, NASH
Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
This study is to assess the diagnostic performance of the LiverFASt Test for assessing fibrosis staging scores compared to the assessment of liver tissue pathology from liver biopsy.
- Trial name
- NCT03980912
- Testing
- LiverFASt
- Where
- United States
- Sponsor
- Fibronostics USA, Inc
Non-alcoholic Fatty Liver Disease, Diabetes
De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease
The worldwide epidemic of obesity is paralleled with increased cases of non-alcoholic liver disease (liver fat accumulation) and diabetes.
- Trial name
- LINC (NCT00714129)
- Testing
- Dietary intervention (calorie restricted diet)
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Steatohepatitis, Nonalcoholic, Steatosis of Liver
Ketogenic Diet in MASLD-related cACLD
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD.
- Conditions
- Steatohepatitis, Nonalcoholic, Steatosis of Liver, Cirrhosis, Liver
- Trial name
- NCT06537466
- Testing
- Mediterranean diet, Very Low Ketogenic Diet
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Palermo
Non-Alcoholic Fatty Liver Disease, Dietary Modification
Chia Supplementation and Non Alcoholic Fatty Liver Disease
Parallel to epidemic obesity, non-alcoholic fatty liver disease (NAFLD) prevalence has markedly increased during the last years, and recent data point out that one of three adults courses with this disease.
- Trial name
- NCT03942822
- Testing
- Milled chia seeds
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Omics-based Predictors of NAFLD/Potential NASH
The cascade of care for the non-alcoholic fatty liver disease (NAFLD) and its progression to non-alcoholic steatohepatitis (NASH) requires crossing the barriers for their diagnosis and treatment.
- Trial name
- NCT05301231
- Testing
- Genomics (DNA Extraction), Epi-genomics, Proteomics (Glycoproteomics)
- Where
- Egypt
- Volunteers
- 450 people
- Sponsor
- National Research Centre, Egypt
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Non-Alcoholic Fatty Liver Disease
The Influence of SARS-CoV-2 Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution
Unhealthy lifestyle represents a key element fueling the non-alcoholic fatty liver disease (NAFLD) onset and worsening. The investigators aimed to evaluate the effects of confinement-related lifestyle changes experienced during…
- Trial name
- NCT05416970
- Testing
- SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES
- Where
- Italy
- Volunteers
- 122 people
- Sponsor
- University of Campania Luigi Vanvitelli
Insulin Resistance, Type2 Diabetes Mellitus
High-fat Overfeeding, Hepatokines and Appetite Regulation
The present study will investigate the effect of high-fat overfeeding on a group of liver-secreted proteins linked to worsened blood sugar control, as well as proteins involved in appetite control.
- Conditions
- Insulin Resistance, Type2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, Obesity
- Trial name
- OVEREAT (NCT03369145)
- Testing
- High-fat diet
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Loughborough University
Non-Alcoholic Fatty Liver Disease, Fat Soluble Vitamin Deficiencies and Disorders
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease
Excessive or insufficient levels of vitamins in the body can affect health. With the prevalence of obesity and MetS, NAFLD has become the leading cause of chronic liver disease and abnormal liver biochemical indicators in health…
- Trial name
- NCT06512701
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Morbid Obesity, Non Alcoholic Steatohepatitis
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Abstract: Fatty liver most frequently corresponds to a fat overload of the liver. It is usually classified as alcoholic steatosis or non-alcoholic steatosis.
- Trial name
- FIRM (NCT01695083)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NASH - Nonalcoholic Steatohepatitis
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects.
To evaluate the safety, tolerability and Pharmacokinetic profile of SNP-630 when oral administered to healthy subjects.
- Trial name
- NCT04808154
- Testing
- SNP-630
- Where
- Taiwan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Sinew Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.